Department of Medical Genetics, China Medical University, Shenyang, Liaoning, China.
Cancer Lett. 2010 Jun 1;292(1):41-7. doi: 10.1016/j.canlet.2009.11.007. Epub 2009 Nov 28.
S100A4 has been found to be over-expressed in gastric cancer and associated with poor prognosis of the patients, yet the exact role and molecular mechanism of S100A4 in gastric cancer has not been determined. We found that S100A4 inhibition by RNAi lead to reduced proliferation and increased apoptosis of gastric cancer cell line BGC823. Intratumoral injection of pS100A4-shRNA suppressed tumor growth in nude mice. We also found that S100A4 inhibition decreased the expression of both NF-kappaB p65 and phospho(Ser32)-I-kappaB-alpha. Our results suggested that S100A4 may be an attractive candidate for the therapeutic targeting of gastric cancer.
S100A4 在胃癌中被发现过表达，并与患者的不良预后相关，但其在胃癌中的确切作用和分子机制尚不清楚。我们发现，通过 RNAi 抑制 S100A4 可导致胃癌细胞系 BGC823 的增殖减少和凋亡增加。pS100A4-shRNA 的瘤内注射可抑制裸鼠肿瘤生长。我们还发现，S100A4 抑制可降低 NF-κB p65 和磷酸化(Ser32)-I-κB-α的表达。我们的研究结果表明，S100A4 可能是胃癌治疗靶点的有吸引力的候选物。
